Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects

Michael C. Heinrich

doi:10.2174/1389557043487394

Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects

Michael C. Heinrich

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

Original language	English (US)
Pages (from-to)	255-271
Number of pages	17
Journal	Mini-Reviews in Medicinal Chemistry
Volume	4
Issue number	3
DOIs	https://doi.org/10.2174/1389557043487394
State	Published - Mar 2004

Keywords

AML
FLT3
KIT
Kinase inhibitor
PDGFR
Tyrosine kinase

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery
Cancer Research

Access to Document

10.2174/1389557043487394

Cite this

@article{438e2dfe7cd847578b6c6cd0635f8c71,

title = "Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects",

abstract = "Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.",

keywords = "AML, FLT3, KIT, Kinase inhibitor, PDGFR, Tyrosine kinase",

author = "Heinrich, {Michael C.}",

year = "2004",

month = mar,

doi = "10.2174/1389557043487394",

language = "English (US)",

volume = "4",

pages = "255--271",

journal = "Mini-Reviews in Medicinal Chemistry",

issn = "1389-5575",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - Targeting FLT3 kinase in acute myelogeneous leukemia

T2 - Progress, perils, and prospects

AU - Heinrich, Michael C.

PY - 2004/3

Y1 - 2004/3

N2 - Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

AB - Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

KW - AML

KW - FLT3

KW - KIT

KW - Kinase inhibitor

KW - PDGFR

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=2342522071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342522071&partnerID=8YFLogxK

U2 - 10.2174/1389557043487394

DO - 10.2174/1389557043487394

M3 - Review article

C2 - 15032673

AN - SCOPUS:2342522071

SN - 1389-5575

VL - 4

SP - 255

EP - 271

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

IS - 3

ER -

Targeting FLT3 kinase in acute myelogeneous leukemia: Progress, perils, and prospects

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this